-
Uncategorized4 months ago
Trustworthy AI in clinical oversight
AI can accelerate clinical work and preserve traceability, but only if users can trust it. Read More
-
Uncategorized4 months ago
6 FDA Decisions To Watch in Q2 2026
6 FDA Decisions To Watch in Q2 2026
-
Uncategorized4 months ago
Common Pitfalls That Delay Regulatory Submissions, and How to Prevent Them
Common Pitfalls That Delay Regulatory Submissions, and How to Prevent Them
-
Uncategorized4 months ago
Kailera plots IPO to fund obesity pipeline after one of the biggest raises of 2025
Kailera Therapeutics—one of the biggest money-raisers of 2025—is now seeking to go public as it seeks further funding to push its obesity portfolio through the clinic.Read...
-
Uncategorized4 months ago
StockWatch: Wave Plummets 50% on Obesity Data
Disappointed investors punished Wave Life Sciences (NASDAQ: WVE), causing its shares to lose roughly half their value on Thursday after the RNA-based drug developer reported mixed...
-
Uncategorized4 months ago
Engineering macrophage-targeted trispecific immune cell engagers for tumor immunotherapy
Nature Biotechnology, Published online: 30 March 2026; doi:10.1038/s41587-026-03104-5 Immune cell engagers (ICEs) have emerged as a promising strategy for cancer immunotherapy, but their efficacy in solid...
-
Uncategorized4 months ago
Kailera plans IPO for Phase 3 obesity drug from Hengrui
Kailera plans IPO for Phase 3 obesity drug from Hengrui
-
Uncategorized4 months agoSTAT+: AI drug developer Insilico Medicine and Lilly ink commercialization deal worth up to $2.75 billion
Alex Zhavoronkov, CEO of Insilico Medicine, can’t stop complimenting Eli Lilly. “Lilly is better in AI than Insilico, and no other company is better in AI...
-
Uncategorized4 months ago
#ACC26: Merck leans toward lower Winrevair dose in Phase 3 trial for rare form of heart failure
#ACC26: Merck leans toward lower Winrevair dose in Phase 3 trial for rare form of heart failure
-
Uncategorized4 months ago
#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibody
#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibody
Renewed Importance of CEX in Monoclonal-Antibody Purification
